{"id":"methysergide","rwe":[{"pmid":"41750190","year":"2026","title":"Neurotransmitter Mechanisms of Ketamine and Ketamine-Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABA(A) Contributions.","finding":"","journal":"Brain sciences","studyType":"Clinical Study"},{"pmid":"40758546","year":"2025","title":"Ozanimod, a functional sphingosine-1-phosphate receptor 1 antagonist, restores brainstem descending pain pathways in murine models of neuropathic pain.","finding":"","journal":"Pain","studyType":"Clinical Study"},{"pmid":"40443063","year":"2025","title":"Monitoring Cortical Spreading Depolarization: Advancements and Applications in Neurocritical Care: A Scoping Review.","finding":"","journal":"Synapse (New York, N.Y.)","studyType":"Clinical Study"},{"pmid":"40414579","year":"2025","title":"Schinus terebinthifolius essential oil and its major component delta-3-carene induce antinociception mediated by serotonergic receptors.","finding":"","journal":"Journal of ethnopharmacology","studyType":"Clinical Study"},{"pmid":"40162624","year":"2025","title":"Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model.","finding":"","journal":"Future science OA","studyType":"Clinical Study"}],"tags":[{"label":"methysergide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"HTR1D","category":"gene"},{"label":"N02CA04","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Migraine Prevention","category":"indication"},{"label":"Approved 1960s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"},{"label":"Vasoconstrictor Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/conivaptan","drug":"conivaptan","action":"Avoid combination","effect":"May interact with Conivaptan","source":"DrugCentral","drugSlug":"conivaptan"},{"url":"/drug/delavirdine","drug":"delavirdine","action":"Avoid combination","effect":"May interact with Delavirdine Mesylate","source":"DrugCentral","drugSlug":"delavirdine"},{"url":"/drug/mibefradil","drug":"mibefradil","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride","source":"DrugCentral","drugSlug":"mibefradil"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Nefazodone","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Avoid combination","effect":"May interact with Nelfinavir Mesylate","source":"DrugCentral","drugSlug":"nelfinavir"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METHYSERGIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:00:42.551542+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:01:05.584339+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:00:48.419775+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYSERGIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:00:49.038417+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2c (5-HT2c) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:00:50.201404+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200938/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:00:49.853500+00:00"}},"allNames":"deseril","offLabel":[],"synonyms":["deseril","methysergide","methysergid","methysergide maleate"],"timeline":[{"date":"1962-02-12","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Methysergide (Deseril) is a marketed drug used for migraine prevention, with a key composition patent expiring in 2028. Its mechanism of blocking serotonin receptors sets it apart in the same class as dihydroergotamine and ergotamine, where it competes with a patent-protected dihydroergotamine and off-patent ergotamine generics. The primary risk is the potential loss of market share to the off-patent ergotamine generics, which may erode Methysergide's market position post-2028 patent expiry.","approvals":[{"date":"1962-02-12","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Deseril","ecosystem":[{"indication":"Migraine Prevention","otherDrugs":[{"name":"propranolol","slug":"propranolol","company":"Baxter Hlthcare Corp"},{"name":"timolol","slug":"timolol","company":"Aton"},{"name":"topiramate","slug":"topiramate","company":"Janssen Pharms"},{"name":"valproic acid","slug":"valproic-acid","company":"Abbvie"}],"globalPrevalence":1000000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","novelty":"Follow-on","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR1F","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1F","protein":"5-hydroxytryptamine receptor 1F"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"},{"gene":"HTR1B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1B","protein":"5-hydroxytryptamine receptor 1B"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","drugClass":"methysergide","explanation":"","oneSentence":"","technicalDetail":"Deseril acts as a selective 5-HT2A receptor antagonist, competitively inhibiting the binding of serotonin to its receptor sites, thereby reducing the excitatory neurotransmission that contributes to migraine pathophysiology."},"commercial":{"launchDate":"1962","_launchSource":"DrugCentral (FDA 1962-02-12, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1775","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHYSERGIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:41:00.844458","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:01:05.584434+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dihydroergotamine","drugSlug":"dihydroergotamine","fdaApproval":"1946-04-12","patentExpiry":"Sep 5, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ergotamine","drugSlug":"ergotamine","fdaApproval":"1948-11-26","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"methysergide","indications":{"approved":[{"name":"Migraine Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":39000000,"globalPrevalence":1000000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Neurology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dihydroergotamine","brandName":"dihydroergotamine","genericName":"dihydroergotamine","approvalYear":"1946","relationship":"same-class"},{"drugId":"ergotamine","brandName":"ergotamine","genericName":"ergotamine","approvalYear":"1948","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"1450","NDDF":"003414","UNII":"XZA9HY6Z98","CHEBI":"CHEBI:584020","VANDF":"4018758","INN_ID":"1000","RXNORM":"203190","UMLSCUI":"C0025842","chemblId":"CHEMBL1200938","ChEMBL_ID":"CHEMBL1065","KEGG_DRUG":"D00681","DRUGBANK_ID":"DB00247","PDB_CHEM_ID":" H8J","PUBCHEM_CID":"9681","SNOMEDCT_US":"11796006","IUPHAR_LIGAND_ID":"134","SECONDARY_CAS_RN":"129-49-7","MESH_DESCRIPTOR_UI":"D008784"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"13%"},"publicationCount":3494,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N02CA04","allCodes":["N02CA04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 4","pmid":"41750190","title":"Neurotransmitter Mechanisms of Ketamine and Ketamine-Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABA(A) Contributions.","journal":"Brain sciences"},{"date":"2025 Nov 1","pmid":"40758546","title":"Ozanimod, a functional sphingosine-1-phosphate receptor 1 antagonist, restores brainstem descending pain pathways in murine models of neuropathic pain.","journal":"Pain"},{"date":"2025 Jul","pmid":"40443063","title":"Monitoring Cortical Spreading Depolarization: Advancements and Applications in Neurocritical Care: A Scoping Review.","journal":"Synapse (New York, N.Y.)"},{"date":"2025 Jun 26","pmid":"40414579","title":"Schinus terebinthifolius essential oil and its major component delta-3-carene induce antinociception mediated by serotonergic receptors.","journal":"Journal of ethnopharmacology"},{"date":"2025 Dec","pmid":"40162624","title":"Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model.","journal":"Future science OA"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1962","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1962-02-12T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:01:05.584434+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}